Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.


Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.
Click here for resources to get patients started on Aimovig®—including via telemedicine

Aimovig® and COVID-19: Frequently Asked Questions

We recognize this may be a challenge and stressful time. The team behind Aimovig® will continue to keep you informed about important information related to Aimovig® and COVID-19. We are committed to continuing to deliver Aimovig® to you and your patients.

Below are answers to questions about Aimovig® as it relates to COVID-19.

Aimovig® Product Information & Supply

  • If you have any questions about Aimovig®, you can reach the Amgen medical team via phone at 1-800-772-6436 and the Novartis medical team at 1-888-669-6682. If your patients have any questions about their treatment plan because of concerns about COVID-19, it is important that they consult with you, their healthcare provider.
  • We continue to provide an uninterrupted supply of medicines for patients around the world and we do not currently anticipate a shortage of our medicines due to COVID-19.
  • Aimovig® has a global manufacturing network. However, we do not manufacture any products in China.
  • We continue to provide an uninterrupted supply of medicines for patients around the world and we do not currently anticipate a shortage of our medicines due to COVID-19.

Taking Aimovig®

  • During the COVID-19 pandemic, cleaning with soap and water may be an alternative. Our Instructions for Use (IFU) for the 70 mg/mL SureClick autoinjector and 140 mg/mL SureClick autoinjector provide guidance that alcohol wipes are preferred. However, if your patients are out of alcohol wipes, please ask them to consult you.

Aimovig® & COVID-19

  • There are no data to inform on the incidence or severity of COVID-19 infection in patients receiving Aimovig®.
  • Aimovig® is a biologic medicine that selectively targets and blocks the calcitonin gene-related peptide receptor (CGRP-R), disrupting a key component of migraine pathophysiology.1,2 In clinical trials, there has been no evidence that Aimovig® suppresses the immune system.3
    If you have questions about Aimovig®, you can reach us via phone at 1-800-772-6436 or 1-888-669-6682.
  • As their healthcare provider, we consider you to be in the best position to determine whether your patients should start, discontinue, or re-start taking Aimovig® based on their individual medical situation.

Getting Aimovig®

  • Patient eligibility for extended supply of Aimovig® is mainly dependent on whether their insurance plans allow Aimovig® refills for an extended period - 90 days or more. Some plans are allowing longer extended refills, but this varies from plan to plan.
  • If your patients are eligible for a 90-day/3-month supply of Aimovig®, it needs to be indicated in your prescription.
  • If, in your clinical judgment, a 90-day supply is appropriate for your patient, have your patient ask their pharmacy if a 90-day fill is available—some plans are allowing longer fills of medications.
  • Please note that a 90-day supply must be approved by your patient's insurance plan and may be available during this time as an exception.
  • A new prescription may be necessary for a 90-day supply.
  • Pharmacy delivery: Patients should call their current pharmacy to see if home delivery options are available. Many pharmacies are now offering home delivery, and some even offer it free of charge. Amgen and Novartis have gathered the following information from publicly available sources for common pharmacies that provide delivery of refrigerated products. This list is not comprehensive, and does not endorse any pharmacy*: Walgreens, Publix, Wegmans, Meijer, Giant Eagle, HEB, Albertsons, Schnucks Markets.
    *At the time of this communication these appeared to be available options. Contact the pharmacy directly to confirm availability.
  • Mail order: Patients should use a mail service pharmacy that is contracted with their insurance plan. Once patients have identified their mail service pharmacy, they should call or visit the pharmacy's website for instructions. Normally the patient needs to complete an order form, provide the prescription, and make a payment online or through the mail.
  • If a patient does not know if their insurance covers mail-order prescriptions, have the patient check their insurer’s website or call the members services phone line. They can find this website and phone number on their insurance member ID card.

Paying for Aimovig®

  • We understand that access is a concern for you and your patients. That is why we are committed to helping ensure continuity of care for your patients.
  • Your commercially ensured patients have access to our Commercial Bridge. It covers up to 12 doses and you have up to 90 days to complete a prior authorization on the patient's behalf.
  • You can find the resources you and your patients need to start Aimovig® on AimovigHCP.com, such as Aimovig Ally™ Access Card information, injection video, etc. Your patients can also enroll in our support program or call 1-833-AIMOVIG if they have any questions about the program.
  • Aimovig Ally™ Access Card will cover a 90-day supply. Some plans are allowing longer fills on medications. Note, new prescriptions may be required for a 90-day fill. Ask your patients to discuss with their pharmacist for more information.

Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.

References: 1. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132. 2. Aimovig® (erenumab-aooe) prescribing information, Amgen. 3. Goadsby PJ, Reuter U, Hallström Y, et al. Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine. Poster presented at: 12th European Headache Federation Congress (EHF); September 28–30, 2018; Florence, Italy. 4. Ashina M, Goadsby PJ, Reuter U, et al. Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+-year results of a 5-year, open-label treatment period. Oral presentation at: American Headache Society, 61st Annual Scientific Meeting; July 11-14, 2019; Philadelphia, PA. 5. Sun H, Dodick DW, Silberstein S, et al. Appendix for: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382-390. 6. Ashina M, Tepper SJ, Brandes JL, et al. Efficacy and safety of erenumab (AMG 334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611-1621. 7. Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from an ongoing open-label extension study in episodic migraine. Oral presentation at: American Headache Society, 60th Annual Scientific Meeting; June 28–July 1, 2018; San Francisco, CA. 8. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-434. 9. Tepper SJ, Ashina M, Reuter U, et al. Assessment of the long-term safety and efficacy of erenumab during open-label treatment in subjects with chronic migraine. Poster presented at: American Headache Society, 60th Annual Scientific Meeting; June 28–July 1, 2018; San Francisco, CA. 10. Data on file, Amgen Inc. AMG 334 Clinical Study Report: 20130255 Final Analysis. February 16, 2018. 11. Brossner G, Reuter U, Bonner J, et al. Achievement of ≥ 75% and 100% response in patients treated with erenumab: 24-week results from the STRIVE study. Poster presented at: 18th Congress of the International Headache Society; September 7-10, 2017; Vancouver, Canada. 12. Data on file, Amgen Inc. AMG 334 Abbreviated Clinical Study Report: 20120178. January 28, 2016. 13. Data on file, Amgen Inc. AMG 334 Abbreviated Clinical Study Report: 20120296. July 16, 2018. 14. Data on file, Amgen Inc. AMG 334 Clinical Study Report: 20130255 Final Analysis. February 16, 2018.